Skip to main content
 

Matthew Walsh

Matthew Walsh

Matthew Walsh, General Manager, Biopharma at ixlayer, is responsible for leading the Company’s growth strategy for the commercial Biopharma business unit. In this role, Mr. Walsh leads and is responsible for the management, product portfolio, sales, customer success, operations, and overall performance of the Biopharma business. Mr. Walsh has spent over a decade bringing innovation to commercial Biopharma teams, focused on the intersection of technology, patient analytics, and patient care.

Prior to ixlayer, Mr. Walsh spent seven years at Crossix Solutions, a healthcare data startup which provided analytics solutions that maximized the ROI of Biopharma marketing investments. At Crossix, Mr. Walsh’s role spanned client consulting, product strategy, and product marketing. During his time at Crossix, revenue grew from $10M to $100M resulting in a successful acquisition by Veeva Systems, a leading healthcare software company. Mr. Walsh then spent four years at Veeva, serving on the leadership team of the Crossix Analytics business unit, overseeing growth strategy for the core product suite as well as bringing several new products to market combining the unique data assets of Crossix and the technology footprint of Veeva.

Mr. Walsh holds a bachelor’s degree from Princeton University.

More News

  • Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF

  • AHA Innovators’ Network Member Accurkardia receives FDA Breakthrough Device Designation on New Condition Area

  • Target: BP™ initiative helps more than 9M Americans with hypertension